Stepping Up to the Challenge: The PCP’s Role in HCV Elimination
Infectious DiseasesStepping Up to the Challenge: The PCP’s Role in HCV Elimination
1.0 AMA PRA Category 1 Credit(s) ™ 1.0 AANP Contact Hours
December 18, 2020
The accreditation for this activity has expired.
Primary Audience:
Primary care physicians, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with or at risk of HCV infection.
Relevant Terms:
Addiction Medicine, Substance Abuse
Gregg Sherman, MD
Chief Medical Officer
National Association for Continuing Education
Plantation, FL
Gregg Sherman, MD, Chief Medical Officer, is a Board-Certified Family Physician. He joined NACE in 2002 and has been responsible for overseeing the development of all educational programs that NACE presents. In addition to working with faculty on these activities, Dr. Sherman serves as host and moderator for many of NACE’s live meetings and the NACE Clinical Highlights Podcast show. He is an active member in the CME community and participates in national meetings to share his expertise and advance the delivery of high quality continuing medical education.
Dr. Sherman attended Colgate University for his Bachelor's degree and SUNY Stony Brook School of Medicine. After completing a Family Practice Residency program with the University of Florida, Dr. Sherman began his career as a Family Physician in Margate, Florida where he served the community for fifteen years before joining NACE full time in 2016.
Stacey B. Trooskin, MD, PhD, MPH
Chief Medical Officer
Director of Viral Hepatitis Programs
Jonathan Lax Treatment Center
Philadelphia FIGHT
Philadelphia, Pennsylvania
Stacey B. Trooskin, MD, PhD, MPH is Chief Medical Officer and Director of Viral Hepatitis Programs at Philadelphia FIGHT Community Health Centers and is a faculty member of the Infectious Diseases Division at the University of Pennsylvania. Dr. Trooskin received her MPH in Public Health from Yale University, her PhD (Epidemiology) from Rutgers School of Public Health and her MD from the University of Medicine and Dentistry of New Jersey, at the Robert Wood Johnson School of Medicine. Dr. Trooskin specializes in infectious diseases, HIV medicine, HIV/HCV co-infection, and internal medicine. She has an interest in public health, particularly the epidemiology of hepatitis C and identifying and overcoming barriers to testing and treatment. She recently completed a 3 year term of service as a member of the AASLD/IDSA HCV treatment guidance panel and currently serves as the Chief Medical Advisor to the National Viral Hepatitis Roundtable and is a member of the Technical Advisory Board (TAB) of the Coalition for Global Hepatitis Elimination.| 1. | Demonstrate an understanding of HCV epidemiology and the critical role of primary care providers in HCV elimination. | 2. | Employ American Association for the Study of Liver Diseases/Infectious Diseases Society of America (AASLD/IDSA) HCV guidelines in primary care settings. |
| 3. | Provide monitoring and harm-reduction counseling across the HCV care continuum. |
| 1. | Demonstrate an understanding of HCV epidemiology and the critical role of primary care providers in HCV elimination. |
| 2. | Employ American Association for the Study of Liver Diseases/Infectious Diseases Society of America (AASLD/IDSA) HCV guidelines in primary care settings. |
| 3. | Provide monitoring and harm-reduction counseling across the HCV care continuum. |
This activity is presented by National Association for Continuing Education and Integritas Communications.
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Release Date: December 18, 2020
Expiration Date: December 18, 2021
Target Audience
This activity is intended for primary care physicians, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with or at risk of HCV infection.
Learning Objectives
Upon completion of this program, participants will be better able to:
- Demonstrate an understanding of HCV epidemiology and the critical role of primary care providers in HCV elimination.
- Employ American Association for the Study of Liver Diseases/Infectious Diseases Society of America (AASLD/IDSA) HCV guidelines in primary care settings.
- Provide monitoring and harm-reduction counseling across the HCV care continuum.
Course Summary
This activity is designed to encourage primary care clinicians’ active engagement in the HCV care continuum. Topics will include HCV testing, pretreatment assessment, direct-acting antiviral therapies, post-cure monitoring, and harm-reduction principles and practices.
Faculty
Stacey B. Trooskin, MD, PhD, MPH
Chief Medical Officer
Director of Viral Hepatitis Programs
Jonathan Lax Treatment Center
Philadelphia FIGHT
Philadelphia, Pennsylvania
Planning Committee
Michelle Frisch, MPH, CHCP
Vice President, Operations
National Association for Continuing Education
Plantation, FL
Sheila Lucas, CWEP
Activity Director
National Association for Continuing Education
Plantation, FL
Deborah Paschal, CRNP
Clinical Nurse Practitioner
Philadelphia, PA
Gregg Sherman, MD
Chief Medical Officer/Course Director
National Association for Continuing Education
Plantation, FL
Becky Carney, MSPT
Senior VP, Educational Strategy
Integritas Communications Group
Hoboken, NJ
Jim Kappler, PhD
Integritas Communications Group
Hoboken, NJ
Mara Simpson
Vice President, Account Services
Integritas Communications Group
Hoboken, NJ
Jeanette Ruby, MD
Vice President, Scientific Services
Integritas Communications Group
Hoboken, NJ
Accreditation Information
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and Integritas Communications. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of the National Association for Continuing Education and Integritas Communications. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 1.0 contact hour(s) (which includes .75 hour(s) of pharmacology).
Policy on Faculty and Provider Disclosure
Educational programs sponsored by the National Association for Continuing Education (NACE) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a NACE-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. Any potential conflicts of interest will be resolved prior to the activity.
Per the ACCME, a Commercial Interest is defined as an entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on, patients. Providers of clinical service directly to patients are not considered to be commercial interests - unless the provider of the clinical service is owned, or controlled by, a defined commercial interest.
Resolution of Personal Conflicts of Interest
NACE requires disclosure of relevant financial relationships with the commercial interest from course directors, faculty, members of the activity planning committee, and others in a position to control the content of the educational activity. Any individual who refuses to disclose his or her relationships will be disqualified from any involvement in the planning, development, teaching/presenting, managing, or evaluation of the educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Stacey B. Trooskin has disclosed the following financial relationships:
- Advisory Board Member: Gilead Sciences, Inc.
- Contracted Researcher: Gilead Sciences, Inc.
- Organizational Support: AbbVie
Gregg Sherman has no relevant conflicts of interest with any ACCME-defined commercial interest.
The planning committee reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Michelle Frisch has no relevant conflicts of interest with any ACCME-defined commercial interest.
Sheila Lucas has no relevant conflicts of interest with any ACCME-defined commercial interest.
Deborah Paschal has no relevant conflicts of interest with any ACCME-defined commercial interest.
Gregg Sherman has no relevant conflicts of interest with any ACCME-defined commercial interest.
Becky Carney has no relevant conflicts of interest with any ACCME-defined commercial interest
Mara Simpson has no relevant conflicts of interest with any ACCME-defined commercial interest.
Jeanette Ruby has no relevant conflicts of interest with any ACCME-defined commercial interest.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the posttest and program evaluation. Your posttest will automatically be graded. If you successfully complete the posttest (score of 75% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 75%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
